Overview

Bioequivalence Study of Allopurinol 300 mg Tablets USP Under Fasting Condition

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, cross over comparative pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in normal, healthy, adult, human male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
IPCA Laboratories Ltd.
Treatments:
Allopurinol